All In Biotech

NDA 022436 · Bausch

Xerese

Acyclovir, Hydrocortisone · Topical · Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor; Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor

Last checked: Nov 20, 2026Latest source record: Dec 11, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jul 31, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

396

92 Phase 3, 31 recruiting

FAERS reports

40

24 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 3, 2020.

XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). (1)

Mechanism: Acyclovir is an antiviral drug active against α-herpesviruses and hydrocortisone is an anti-inflammatory drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • XERESE · ACYCLOVIR 5%; HYDROCORTISONE 1% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Acyclovir" as an intervention, any sponsor and status, largest first.

All 396 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain11
  • inflammation9
  • oedema peripheral9
  • pharyngeal paraesthesia9
  • off label use4
  • drug ineffective3
  • herpes zoster3
  • pain in extremity3
  • application site pain2
  • arthropathy2
  • malaise2
  • myocardial infarction2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20141
20155
20165
20174
20182
20194
20204
202111
20221
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xerese (Acyclovir/Hydrocortisone)

2024 spending

$577K

Beneficiaries

244

369 claims

Per beneficiary

$2,364

$243.36 per unit

View as table
YearSpending
2020$513,363
2021$488,534
2022$452,625
2023$482,961
2024$576,763

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 938 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.